Influence of mutation type on prognostic and predictive values of TP53 status in primary breast cancer patients

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00209805%3A_____%2F14%3A%230000544" target="_blank" >RIV/00209805:_____/14:#0000544 - isvavai.cz</a>

Result on the web

<a href="http://www.spandidos-publications.com/or/32/4/1695" target="_blank" >http://www.spandidos-publications.com/or/32/4/1695</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3892/or.2014.3346" target="_blank" >10.3892/or.2014.3346</a>

Result language

angličtina

Original language name

Influence of mutation type on prognostic and predictive values of TP53 status in primary breast cancer patients

Original language description

High rates of mutation in the TP53 tumor suppressor gene have been found in many human cancers, including breast tumors, making p53 one of the most studied proteins in oncology. However, the prognostic and predictive value of alterations in this gene remains ambiguous. To analyze the clinical value of somatic TP53 mutations, we collected clinical and molecular data on 210 women with primary breast cancer. We found significant associations of p53 mutations with tumor grade, metastasis, molecular subtype,Her2 status and inverse correlations with estrogen and progesterone receptor status. Cox proportional hazard analysis confirmed a strong prognostic value of p53 mutation for overall survival rate and highlighted significant interactions with lymph nodeinvolvement and tumor size. In relation to treatment options, TP53 mutations were associated with poor response to anthracyclines and radiotherapy. Categorization of TP53 mutations according to their type and location revealed that patien

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

Result was created during the realization of more than one project. More information in the Projects tab.

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2014

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Oncology reports

ISSN

1021-335X

e-ISSN

—

Volume of the periodical

32

Issue of the periodical within the volume

4

Country of publishing house

GR - GREECE

Number of pages

8

Pages from-to

1695-1702

UT code for WoS article

000342528200050

EID of the result in the Scopus database

—